A Study in Participants With Diabetic Kidney Disease

The primary objective is to determine if LY2382770, administered monthly for 1 year, is more
effective than placebo at slowing the progression of diabetic kidney disease in participants
treated with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor
blocker (ARB).

Main Inclusion Criteria:

- Participants with chronic kidney disease presumed due to diabetes Type 1 or Type 2

- Participants with certain levels of kidney function - serum creatinine (SCr) 1.3 to
3.3 mg/dl (115 to 291 micromol/L) inclusive for women and 1.5 to 3.5 mg/dl (132 to 309
micromol/L) inclusive for men, or an estimated glomerular filtration rate (eGFR) 20 to
60 mL/min/1.73 m²

- Participants with protein in the urine - 24-hour urine protein/creatinine ratio (PCR)
greater than or equal to 800 mg/g (greater than or equal to 91 mg/mmol).

- Participants must be on a stable and acceptable dose of an ACE (angiotensin-converting
enzyme) inhibitor or an ARB (angiotensin II receptor blocker), or not able to tolerate
these medications.

Main Exclusion Criteria:

- Female participants who can become pregnant, are pregnant or breastfeeding

- Participants who have any of the following medical conditions (the site research staff
will discuss these criteria and determine a participant's ability to participate)

- Chronic inflammatory or autoimmune diseases

- Chronic Kidney Disease from causes other than diabetes

- An organ transplant

- Too high a blood pressure

- Viral Hepatitis B or C liver infection, liver cirrhosis, or significant liver
disease

- Recent gastrointestinal bleeding

- Acute kidney injury within the 3 months before screening

- Major surgery within 3 months before screening or plan to have it during the
study period

- HIV infection- the virus that causes AIDS

- Heart disease that is not considered stable

- Cancer that is too recent or other condition which poses too high a risk for
developing cancer

- Required to take drugs that change the immune system